ImmunityBio, ANKTIVA, Nogapendekin Alfa Inbakicept, Bladder Cancer, Non-Muscle-Invasive Bladder Cancer, NMIBC, Papillary Bladder Cancer, BCG-Unresponsive, FDA Approval,

CULVER CITY, Calif., October 14, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced that the U.S. Food...